AartiAsnaniMD
Cardiology • Boston, MADirector of Cardio-Oncology, Beth Israel Deaconess Medical Center
Dr. Asnani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-8800Fax+1 617-632-7620
Summary
- Dr. Aarti Asnani is a Boston-based cardiologist specializing in cardio-oncology. She completed her medical education at Duke University School of Medicine and her residency, fellowship in cardiovascular disease, and post-doctoral fellowship at Massachusetts General Hospital. Dr. Asnani is currently Section Head of Cardio-Oncology at Beth Israel Deaconess Medical Center and serves as an attending physician at Massachusetts General Hospital. Her research includes publications on cardiotoxicity and the impact of cancer therapies on cardiovascular health, with work published in prominent journals such as Nature Cardiovascular Research and Cardiology Clinics.
Education & Training
Massachusetts General HospitalPost-Doctoral Fellowship, 2013 - 2017- Massachusetts General HospitalFellowship, Cardiovascular Disease, 2011 - 2014
- Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Duke University School of MedicineClass of 2008
Certifications & Licensure
MA State Medical License 2011 - 2026
American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) ...Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A de Boer
European Journal of Heart Failure. 2025-03-11 - Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.Amin H Nassar, Sarah Abou Alaiwi, Talal El Zarif, Ryan Denu, Walid Macaron
Journal for Immunotherapy of Cancer. 2025-03-03 - 2 citationsPre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy.Maria J Fernandez Turizo, Eunice Kim, Cancan Zhang, Tuyen Yankama, Gottfried Von Keudell
The Oncologist. 2025-02-06
Authored Content
- Ibrutinib-Associated CardiotoxicityJanuary 2020
- Ibrutinib-Associated CardiotoxicityJanuary 2020
Press Mentions
Researchers ID Protein That May Protect the Heart During Certain Cancer Treatment RegimensDecember 27th, 2022- Researchers ID Protein That May Protect the Heart During Certain Cancer Treatment RegimensDecember 27th, 2022
Heart Health Month Special Edition of BIDMC’s Research & Health News DigestFebruary 4th, 2020- Join now to see all
Grant Support
- Hemopexin as an Early Biomarker of Anthracycline Cardiac ToxicityBETH ISRAEL DEACONESS MEDICAL CENTER2022–2027
Professional Memberships
- Member
- Member
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
